Two Pore Guys and Maxim Integrated Announce Technology Collaboration and Investment

January 09, 2018 06:00 AM Pacific Standard Time SANTA CRUZ, Calif.–(BUSINESS WIRE)–Two Pore Guys (2PG) announced today that it is collaborating with Maxim Integrated Products, Inc. (NASDAQ: MXIM), on a series of analog signal processing technologies for 2PG’s solid-state nanopore diagnostic testing platform. As part of this collaboration, Maxim has invested in 2PG through its... Read more

10x Genomics Announces Collaboration with Berry Genomics to Develop Next Generation Noninvasive Prenatal Testing (NIPT)

–Collaboration will be a new service offering for Berry Genomics and entry point for 10x Genomics into the NIPT Market in China– PLEASANTON, CA. and BEIJING, CHINA —January 8, 2018—10x Genomics, Inc., a company focused on accelerating genomic discovery, and Berry Genomics Co. Ltd (SZSE:000710), a company devoted to developing and offering genomic solutions for... Read more

Thermo Fisher Scientific Expands Oncomine Portfolio for Liquid Biopsy and Immuno-oncology Clinical Research

Thermo Fisher Scientific Expands Oncomine Portfolio for Liquid Biopsy and Immuno-oncology Clinical Research New pan-cancer cell-free total nucleic acid (cfTNA) assay and FFPE-based tumor mutation load analysis assay, coupled with novel Ion AmpliSeq HD technology, extend industry-leading Oncomine menu and enable panel design customization CARLSBAD, Calif., Jan. 8, 2018 /PRNewswire/ — Thermo Fisher Scientific has expanded... Read more

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment

Basel, 08 January 2018 Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment Companies aim to develop jointly-branded clinical decision support software for faster, more accurate, more confident decision-making, enabling earlier diagnosis and individualised treatment Partnership will apply advanced analytics to in-vivo data from GE’s medical... Read more

GE, Roche Enter Partnership to Develop Integrated Digital Diagnostics Platform to Improve Oncology and Critical Care Treatment

Chicago, USA Jan 8, 2018 – GE Healthcare has entered into a strategic, long-term partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients. The two companies... Read more

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment

Basel, 08 January 2018 Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment Companies aim to develop jointly-branded clinical decision support software for faster, more accurate, more confident decision-making, enabling earlier diagnosis and individualised treatment Partnership will apply advanced analytics to in-vivo data from GE’s medical... Read more

Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas

Basel, 04 January 2018 Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas New technology allows better testing and monitoring of HIV patients living in remote settings For the first time, patient plasma samples no longer need refrigeration during transport to the lab Card meets... Read more

Illumina and KingMed Diagnostics Partner to Develop Next-Generation Sequencing Technology for Chinese FDA Approval

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and KingMed Diagnostics (SSE: 603882.SS) today announced an agreement to jointly develop novel oncology and hereditary disease testing applications utilizing Illumina’s next-generation sequencing (NGS) technology. The collaboration is a significant step toward China Food and Drug Administration (CFDA) review and approval, and serves as a starting point to deliver... Read more

Seegene develops world’s first multiplex MDx assays with its AI system

Seoul, South Korea – Jan 3, 2018 – Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered in South Korea, announced today that, utilizing a newly created artificial intelligence (“AI”) based assay development system, the company succeeded in developing molecular diagnostics (“MDx”) assays in only four (4) days. These assays are high multiplex... Read more

Announcement on investigator-initiated clinical trial of neoadjuvant combination therapy with HF10 and Nivolumab

Announcement on investigator-initiated clinical trial of neoadjuvant combination therapy with HF10 and Nivolumab Announcement on investigator-initiated clinical trial of neoadjuvant combination therapy with HF10 and Nivolumab Kusatsu Shiga, Japan―December 21 , 2017― Takara Bio Inc. (Takara Bio) announced today it has entered into an agreement with Huntsman Cancer Institute (HCI) at the University of Utah... Read more